<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Plasma concentration of <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) was determined in elderly patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> or <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> who were treated with subcutaneous injection of Ara-C (Ara-C s.c.; 10 mg/m2/12 hr, 14-21 days), continuous drip infusion of Ara-C (Ara-C d.i.v.; 20 mg/m2/day, 24 hr 14 days) and/or oral administration of <z:chebi fb="0" ids="28680">cytarabine</z:chebi> ocfosfate (SPAC) (SPAC p.o.; 100 mg-300 mg/body/day, 14 days) by radioimmunoassay </plain></SENT>
<SENT sid="1" pm="."><plain>In the Ara-C s.c. patients, the peak plasma level (Cmax) of Ara-C was 103 ng/ml and the time to reach Cmax was 15 min </plain></SENT>
<SENT sid="2" pm="."><plain>The elimination half-like (t1/2) was 25 min and no accumulation was detected after 14 days of consecutive Ara-C s.c. administrations </plain></SENT>
<SENT sid="3" pm="."><plain>In the SPAC p.o. patients, Cmax of Ara-C was 3-8 ng/ml and it took 3-5 days to reach Cmax </plain></SENT>
<SENT sid="4" pm="."><plain>The plasma concentration level of Ara-C remains almost at the Cmax level during the SPAC p.o. administration and it remained higher than 0.32 ng/ml for as long as 15 days after the end of administration </plain></SENT>
<SENT sid="5" pm="."><plain>In a Ara-C d.i.v. patient, plasma level of Ara-C was detected 4-7 ng/ml during the administration (day 7 through day 14) </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> patients bone marrow suppression was observed after chemotherapy regardless of regimen, and there was no significant difference between nadir peripheral cell blood counts of Ara-C s.c. patients and SPAC p.o. patients </plain></SENT>
</text></document>